

 Early Warning System

IFC-39904

UCL Pharma



---

## Quick Facts

<b>Countries</b>	Kenya
<b>Financial Institutions</b>	International Finance Corporation (IFC)
<b>Status</b>	Proposed
<b>Bank Risk Rating</b>	B
<b>Voting Date</b>	2018-05-10
<b>Borrower</b>	UNIVERSAL CORPORATION LTD
<b>Sectors</b>	Education and Health
<b>Investment Amount (USD)</b>	\$ 10.00 million



---

## Project Description

Universal Corporation Limited ('UCL' or the 'Company' - <http://ucl.co.ke/>) was established in 1996, starting with a small manufacturing unit in Nairobi's Industrial Area. The business experienced significant growth and thus, set up a state of the art manufacturing plant about 40km outside Nairobi, in Kikuyu Town. UCL is Sub-Saharan Africa's (ex-South Africa) largest and one of the two World Health Organization (WHO) pre-qualified pharmaceutical manufacturers. The company's manufacturing facility and production layout meets the basic GMP requirements with systems and procedures developed as per WHO GMP requirements. UCL manufactures over 100 formulations including tablets, capsules, syrups & suspensions, ointments & creams which it supplies to mostly fragile and conflict affected states (FCS) and low-income IDA countries (LIIDA) in Southern and East Africa.

The project involves a senior loan of up to US\$10 million in UCL, to help finance the upgrade and development plans of their manufacturing plant.



---

## Investment Description

- International Finance Corporation (IFC)

## Private Actors

- Universal Corporation Limited (Parent Company)

Universal Corporation Limited ('UCL' or the 'Company' - <http://ucl.co.ke/>) was established in 1996, starting with a small manufacturing unit in Nairobi's Industrial Area. The business experienced significant growth and thus, set up a state of the art manufacturing plant about 40km outside Nairobi, in Kikuyu Town. UCL is Sub-Saharan Africa's (ex-South Africa) largest and one of the two World Health Organization (WHO) pre-qualified pharmaceutical manufacturers. The company's manufacturing facility and production layout meets the basic GMP requirements with systems and procedures developed as per WHO GMP requirements. UCL manufactures over 100 formulations including tablets, capsules, syrups & suspensions, ointments & creams which it supplies to mostly fragile and conflict affected states (FCS) and low-income IDA countries (LIIDA) in Southern and East Africa.



---

## Contact Information

Contact Person: Perviz Rajnikant Dhanani

### ACCOUNTABILITY MECHANISM OF IFC

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at [CAO@worldbankgroup.org](mailto:CAO@worldbankgroup.org). You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org/>



---

**Bank Documents**

- [Project Information](#)